Latest research on Raloxifene

A second generation selective estrogen receptor modulator (SERM) used to prevent osteoporosis in postmenopausal women. It has estrogen agonist effects on bone and cholesterol metabolism but behaves as a complete estrogen antagonist on mammary gland and uterine tissue. [PubChem]

Latest findings

The first trials [13] have suggested that both Tamoxifen and Raloxifene may reduce breast cancer rates. [source, 1999]
His PSA continued to rise post-radiotherapy, and he was enrolled in the Evista trial and started on Gefitinib [1]. [source]
X’s PSA rose to 4.08, he was taken off the Evista trial and started on the AVIAS trial, which randomized patients to androgen blockade followed by Dutasteride, 0.5 mg daily, vs. placebo to assess whether the length of the off treatment interval in men receiving intermittent androgen deprivation therapy for localized prostate cancer could be increased [2]. [source]